Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares UltraPro Short S&P500 ETF
SPXU
5
Tradr 2X Short TSLA Daily ETF
TSLQ
US Stock MarketDetailed Quotes
ARQT Arcutis Biotherapeutics
- 14.910
- +0.160+1.08%
Close Apr 30 16:00 ET
- 14.900
- -0.010-0.07%
Post 16:59 ET
1.77BMarket Cap-12.85P/E (TTM)
15.000High14.191Low1.28MVolume14.385Open14.750Pre Close18.85MTurnover1.50%Turnover RatioLossP/E (Static)118.64MShares17.75052wk High11.23P/B1.27BFloat Cap6.99052wk Low--Dividend TTM85.24MShs Float40.880Historical High--Div YieldTTM5.49%Amplitude1.760Historical Low14.773Avg Price1Lot Size
Arcutis Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 54.60%-112.16M | 98.67%-748K | 21.13%-34.69M | 32.14%-45.12M | 60.67%-31.6M | 4.14%-247.06M | 20.86%-56.24M | 35.03%-43.98M | -7.27%-66.49M | -41.02%-80.34M |
| Net income from continuing operations | 46.58%-140.04M | 83.72%-10.79M | 7.21%-41.54M | 26.28%-52.33M | 55.83%-35.38M | 15.83%-262.14M | 7.96%-66.28M | 58.44%-44.77M | -5.32%-70.99M | -24.53%-80.1M |
| Operating gains losses | -132.86%-279K | --150K | --226K | ---112K | ---543K | --849K | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 70.87%2.6M | 18.96%458K | 270.03%1.43M | -9.07%351K | -1.38%358K | 62.85%1.52M | 10.95%385K | 37.23%387K | 149.03%386K | 142.00%363K |
| Other non cash items | 32.39%5.81M | 143.42%2.7M | -18.43%903K | 1.28%1.11M | 1.85%1.1M | -86.52%4.39M | 1.09%1.11M | -96.37%1.11M | 129.89%1.09M | 129.51%1.08M |
| Change In working capital | 35.83%-15.08M | -481.27%-1.57M | 58.56%-3.8M | 25.48%-4.27M | 39.57%-5.44M | -130.97%-23.5M | 105.54%411K | -844.53%-9.18M | -60.30%-5.73M | -2,029.08%-9.01M |
| -Change in receivables | -172.40%-47.26M | -121.06%-14.13M | -651.54%-16.61M | -16.65%-5.18M | -163.21%-11.35M | -105.12%-17.35M | -6.02%-6.39M | 9.09%-2.21M | ---4.44M | ---4.31M |
| -Change in inventory | 92.88%-400K | -134.02%-265K | 117.77%611K | 67.08%-633K | 89.10%-113K | 25.21%-5.62M | 124.29%779K | 20.15%-3.44M | ---1.92M | ---1.04M |
| -Change in prepaid assets | 89.00%-948K | -104.50%-66K | 50.53%-4.25M | -335.50%-2.17M | 329.32%5.54M | -348.30%-8.62M | 24.98%1.47M | -3,680.42%-8.59M | -55.27%921K | ---2.42M |
| -Change in payables and accrued expense | 291.74%34.26M | 176.84%13.08M | 218.16%16.63M | 3,291.80%3.89M | 160.94%660K | 217.11%8.75M | 491.98%4.72M | -33.32%5.23M | 97.80%-122K | -222.32%-1.08M |
| -Change in other current liabilities | -11.87%-735K | -11.90%-188K | -12.12%-185K | -10.98%-182K | -12.50%-180K | -51.73%-657K | -12.00%-168K | -52.78%-165K | -86.36%-164K | -83.91%-160K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 54.60%-112.16M | 98.67%-748K | 21.13%-34.69M | 32.14%-45.12M | 60.67%-31.6M | 4.14%-247.06M | 20.86%-56.24M | 35.03%-43.98M | -7.27%-66.49M | -41.02%-80.34M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -84.01%28.82M | 156.08%34.88M | 86.12%84.78M | -169.72%-62.14M | -126.63%-28.7M | 306.69%180.23M | -247.36%-62.19M | 123.09%45.55M | 69.54%89.12M | 604.39%107.75M |
| Net PPE purchase and sale | 66.59%-143K | --0 | -123.44%-143K | --0 | --0 | -28.53%-428K | 95.12%-6K | -966.67%-64K | -245.00%-276K | 33.87%-82K |
| Net intangibles purchase and sale | ---5M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | -81.20%33.96M | 164.13%39.88M | 86.17%84.92M | -169.51%-62.14M | -126.61%-28.7M | 382.65%180.66M | -246.91%-62.18M | 126.17%45.61M | 69.81%89.39M | 599.26%107.83M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -84.01%28.82M | 156.08%34.88M | 86.12%84.78M | -169.72%-62.14M | -126.63%-28.7M | 306.69%180.23M | -247.36%-62.19M | 123.09%45.55M | 69.54%89.12M | 604.39%107.75M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -34.66%66.2M | -198.11%-97.41M | -54.56%394K | 36.36%1.46M | 161,664.00%161.76M | -66.43%101.32M | 10,221.10%99.29M | -99.70%867K | -5.66%1.07M | -99.32%100K |
| Net issuance payments of debt | ---100M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net common stock issuance | 63.48%161.68M | --0 | --0 | --0 | --161.68M | -43.82%98.9M | --98.9M | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | 86.62%4.52M | 567.27%2.59M | -54.56%394K | 36.36%1.46M | -18.00%82K | -17.56%2.42M | -59.67%388K | 48.46%867K | -5.66%1.07M | -61.69%100K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -34.66%66.2M | -198.11%-97.41M | -54.56%394K | 36.36%1.46M | 161,664.00%161.76M | -66.43%101.32M | 10,221.10%99.29M | -99.70%867K | -5.66%1.07M | -99.32%100K |
| Net cash flow | ||||||||||
| Beginning cash position | 62.78%89.32M | 24.98%135.47M | -19.95%84.89M | 131.65%190.71M | 62.78%89.32M | -44.00%54.88M | 30.95%108.4M | 69.00%106.04M | 15.91%82.33M | -44.00%54.88M |
| Current changes in cash | -149.67%-17.14M | -230.61%-63.28M | 1,975.78%50.48M | -546.42%-105.8M | 268.87%101.46M | 180.01%34.5M | 31.40%-19.14M | -87.86%2.43M | 386.09%23.7M | 202.02%27.51M |
| Effect of exchange rate changes | -370.00%-235K | -444.12%-234K | 230.67%98K | -388.89%-26K | -40.38%-73K | ---50K | --68K | ---75K | --9K | ---52K |
| End cash Position | -19.45%71.95M | -19.45%71.95M | 24.98%135.47M | -19.95%84.89M | 131.65%190.71M | 62.78%89.32M | 62.78%89.32M | 30.95%108.4M | 69.00%106.04M | 15.91%82.33M |
| Free cash flow | 52.60%-117.3M | 89.78%-5.75M | 20.92%-34.83M | 32.42%-45.12M | 60.71%-31.6M | 11.93%-247.49M | 20.98%-56.25M | 51.41%-44.05M | -7.57%-66.76M | -40.85%-80.43M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now